Page 4 - Program On Regulation News Today

New estimate says taxpayers spent over $140 million to study Truvada as HIV prevention

The nation’s highest court paused a lower court’s decision to nullify approval of the abortion drug mifepristone, keeping the medication available while an appeal moves forward

A Texas judge’s rejection of an FDA-approved drug could chill development and use of other medications.

A Texas federal judge’s ruling to remove the 23-year-old drug mifepristone from the market not only threatens abortion access in the U.S. — it’s also an appalling sideswipe at the

Data suggest confirmatory trials conducted for drugs granted accelerated approval by the FDA have taken a median 3.5 years to complete since 2012.

Direct-to-consumer advertising works at selling drugs. A new study shows, though, that it may not work so well at promoting treatments that are significantly better than other options.

Hussain Lalani, SM ’23, was named STAT Wunderkind for his efforts to tackle high prescription drug prices.

MORGANTOWN — In the competition between brand name pharmaceuticals and their generic counterparts, drug companies use patent gamesmanship to their advantage, one West Virginia University patent expert said.

A new study in JAMA Internal Medicine shines a light on the lack of accountability for pharma execs who engage in criminal activities.

Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing ...